Answers are grounded in this paper and cite their sources.
Systematic review summarizes evidence on vasa previa management, highlighting the need for universal screening and timely interventions.
Vasa previa is a rare but preventable cause of perinatal mortality. Despite increasing awareness, uncertainty persists regarding optimal screening approaches, timing of delivery, and the role of emerging fetoscopic interventions. This review aimed to summarize current evidence on diagnosis, management, and outcomes in pregnancies with prenatally identified vasa previa. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, MEDLINE, Embase, Web of Science, the Cochrane Library, and major trial registries were searched from inception to March 2025. Reference lists and grey literature were screened to identify additional studies. Eligible designs included randomized trials, cohort studies, systematic reviews, and case series with ≥3 patients reporting diagnostic performance, management strategies, or maternal and neonatal outcomes in confirmed vasa previa. Data were extracted independently and synthesized narratively. Twenty-five studies fulfilled the inclusion criteria, representing more than 3000 affected pregnancies. Universal screening with transvaginal ultrasound and color Doppler during the mid-trimester anomaly scan demonstrated sensitivity exceeding 90%, whereas risk-based screening frequently failed to detect clinically significant cases. Planned cesarean delivery at 36–37 weeks was consistently associated with improved neonatal outcomes and reduced iatrogenic prematurity compared with earlier delivery. Studies comparing inpatient and outpatient management showed no clear increase in adverse outcomes among outpatients when strict selection criteria and rapid operative capability were in place. Fetoscopic laser ablation of exposed vessels was reported only in small series and case reports; although technically achievable, the procedure carried meaningful risks, including preterm membrane rupture, bleeding, and fetal loss. Current evidence supports universal screening and scheduled cesarean delivery at 36–37 weeks as the safest strategy. Outpatient management may be appropriate for carefully selected patients. Fetoscopic treatment remains experimental and should be restricted to specialized research settings.
No takes yet. Share an insight, caveat, or question.
Aldiansyah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: